DANA-FARBER CANCER INSTITUTE
- Country
- 🇺🇸United States
- Ownership
- -
- Established
- 1947-01-01
- Employees
- -
- Market Cap
- -
- Website
- http://www.dana-farber.org/
Monitoring of Erythroid Lineage Specific Chimerism Following Allogeneic Hematopoietic Transplantation for Thalassemia Major
- Conditions
- Thalassemia Major
- First Posted Date
- 2007-05-31
- Last Posted Date
- 2012-02-23
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 40
- Registration Number
- NCT00480506
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇮🇷Tehran University of Medical Sciences, Tehran, Iran, Islamic Republic of
Erlotinib in Women With Squamous Cell Carcinoma of the Vulvar
- First Posted Date
- 2007-05-22
- Last Posted Date
- 2015-05-07
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 41
- Registration Number
- NCT00476476
- Locations
- 🇺🇸
Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Women and Infants Hospital of Rhode Island, Providence, Rhode Island, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Donor Dendritic Cells And Donor Lymphocytes in Patients With Relapsed Hematologic Malignancies After Allogeneic Transplant
- Conditions
- Hematologic Malignancy
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2012-03-29
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 25
- Registration Number
- NCT00476177
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Oxaliplatin and Gemcitabine Followed by Radiation Therapy in the Management of Mixed Mullerian Tumors of the Uterus
- Conditions
- Mixed Mullerian Tumors of the Uterus
- Interventions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2018-08-24
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 20
- Registration Number
- NCT00476086
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
ALL Adult Consortium Trial: Adult ALL Trial
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- First Posted Date
- 2007-05-21
- Last Posted Date
- 2024-04-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 112
- Registration Number
- NCT00476190
- Locations
- 🇺🇸
Ohio State University Medical Center, Columbus, Ohio, United States
🇺🇸Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Children's Hospital of Boston, Boston, Massachusetts, United States
The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer
- Conditions
- Metastatic, Androgen Independent Prostate CancerProstate Cancer
- Interventions
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2016-05-16
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 19
- Registration Number
- NCT00459186
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck
- Conditions
- Squamous Cell Carcinoma of Head and Neck
- Interventions
- Drug: DocetaxelDrug: ZD6474
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2013-07-03
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 30
- Registration Number
- NCT00459043
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Loyola University Medical Center/Cardinal Bernadin Cancer Center, Maywood, Illinois, United States
Polyunsaturated Fatty Acids in Treating Patients With Prostate Cancer Undergoing Prostate Biopsy and/or Surgery
- Conditions
- Prostate Cancer
- Interventions
- Dietary Supplement: omega-3 fatty acidsProcedure: biopsy
- First Posted Date
- 2007-04-11
- Last Posted Date
- 2018-07-13
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 232
- Registration Number
- NCT00458549
- Locations
- 🇺🇸
Brigham and Women's Hospital, Boston, Massachusetts, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
Reduced Intensity Stem Cell Transplantation for Chronic Lymphocytic Leukemia Followed by Vaccination
- Conditions
- Chronic Lymphocytic Leukemia
- Interventions
- Biological: GM-K562 vaccineProcedure: stem cell transplantation
- First Posted Date
- 2007-03-01
- Last Posted Date
- 2020-09-17
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 27
- Registration Number
- NCT00442130
- Locations
- 🇺🇸
Dana-Farber Cancer Institute, Boston, Massachusetts, United States
ZD6474, Cetuximab, and Irinotecan in Patients With Metastatic Colorectal Cancer
- Conditions
- Colorectal Cancer
- First Posted Date
- 2007-02-16
- Last Posted Date
- 2012-10-04
- Lead Sponsor
- Dana-Farber Cancer Institute
- Target Recruit Count
- 46
- Registration Number
- NCT00436072
- Locations
- 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States